VIKAND has launched a new subsidiary, VIPHARMA, to supply pharmaceuticals and medical equipment to the maritime sector. The move, reported, establishes a dedicated vehicle to handle the sourcing, management and delivery of medical goods for ships and offshore operations.
The company described VIPHARMA as a global medical and pharmaceutical supply chain solution for the maritime industry. The subsidiary will focus on the full logistical chain for medicines, medical devices, equipment and consumables required to support healthcare at sea.
VIKAND, which the report identified as a global leader in maritime healthcare, said VIPHARMA will help maritime operators navigate the complex processes involved in obtaining and distributing medical supplies. The announcement was carried by reports on 14 September 2026.
The new unit is presented as an attempt to centralise and simplify what the company called a fragmented procurement environment for seagoing medical needs. VIPHARMA is intended to manage multiple aspects of medical supply so ship operators can maintain stocks and readiness without having to coordinate numerous suppliers individually.
Scope of services
According to the report, VIPHARMA will handle pharmaceuticals, medical devices, equipment and consumables. The subsidiary’s remit covers sourcing and the logistical arrangements necessary to deliver these items to vessels and maritime facilities.
What this means for operators
VIKAND framed VIPHARMA’s offering as aimed at reducing administrative burdens for shipowners and managers by providing a single point of contact for maritime medical supplies. The company positioned the service as assisting operators to maintain medical capability aboard ships and offshore units by streamlining procurement and distribution.
VIKAND’s announcement did not list specific product lines, service tiers or geographic hubs in the material supplied to the reporter. The report confines its detail to the creation of the subsidiary and its stated purpose of supplying and managing maritime medical requirements on a global basis.
Industry observers will watch how VIPHARMA integrates with existing medical and logistics networks that serve shipping and offshore energy projects. The concept of a dedicated maritime pharmaceutical supply chain reflects broader attention to shipboard healthcare resilience and to ensuring prompt access to regulated medical items at sea.
VIKAND’s launch of VIPHARMA represents a strategic expansion of its maritime healthcare activities, signalling an intent to address the specialised logistical and regulatory challenges of delivering medical supplies to vessels worldwide. The company presented the new subsidiary as a commercial response to those operational needs.